Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.

Clinical and translational science - 1 May 2022

Nader Ahmed, Mostafa Nael M, Kim Elaine, Shebley Mohamad

Abstract excerpt

This study evaluated the effect of repeated doses of elagolix on the pharmacokinetics (PK) of omeprazole and its metabolites in healthy premenopausal female subjects. Adult premenopausal female subjects (N = 20) received a single oral dose of omeprazole (40 mg) on day 1 and day 11 and oral doses of elagolix (300 mg) twice-daily on days 3-11. Serial blood samples for assay of omeprazole and its metabolites were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Genotype

Share to Omeprazole

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35137535
DOI: 10.1111/cts.13247
PMCID: PMC9099122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.PMID 35137535Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.Semantic proximity Read ↗

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.Semantic proximity Read ↗

Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro.Semantic proximity Read ↗

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.Semantic proximity Read ↗

Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.Semantic proximity Read ↗

Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.Semantic proximity Read ↗

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.Semantic proximity Read ↗

Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study.Semantic proximity Read ↗

Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.